Zai Lab has achieved a significant milestone with the European Medicines Agency (EMA) granting orphan drug designation (ODD) for zocilurtatug pelitecan (zoci), an investigational antibody-drug conjugate (ADC) targeting DLL3 for the treatment of pulmonary neuroendocrine carcinomas (NECs). This designation is pivotal as it not only underscores the potential of zoci in addressing unmet medical needs in a rare and aggressive cancer type but also facilitates the development process by providing various incentives, including market exclusivity and reduced regulatory fees.
The context of this development is critical, as pulmonary NECs represent a challenging area in oncology with limited treatment options available. The orphan drug status may enhance Zai Lab’s ability to attract investment and partnerships, which are essential for advancing clinical trials and bringing innovative therapies to market. As the competitive landscape in oncology continues to evolve, zoci’s designation could position Zai Lab as a key player in the niche of targeted therapies for rare cancers.
Get started today with Solo access →
